C4 Therapeutics (CCCC)

• Market cap: $351M
• 1 day: 1.06%
• 5 days: -10.66%
• 1 month: -19.72%
• 3 months: -31.98%
• 6 months: -1.72%
• Year to date: 47.67%
• 1 year: 27.8%
• 5 years: -93.25%
• 10 years: -88.82%
• Sector: Healthcare
• Industry: Biotechnology

About: C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Employees: 104